10-Q - CANN - Equibles

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑ **** Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended September 30, 2021.

☐ **** Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from ____________ to ____________.

Commission file number: 000-54457

GENERAL CANNABIS CORP

(Exact name of registrant as specified in its charter)

Colorado		90-1072649
(State of incorporation)		(IRS Employer Identification No.)

1901 S Navajo Street Denver , CO ** 80223**
(Address of principal executive offices) (Zip Code)

( 303 ) 759-1300
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered	Ticker symbol
N/A	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes þ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☑	Smaller reporting company	☑
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

As of November 5, 2021, there were 84,797,955 issued and outstanding shares of the Company's common stock.

Table of Contents GENERAL CANNABIS CORP

FORM 10-Q

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	28
Item 4.	Controls and Procedures	28

PART II. OTHER INFORMATION		29

Item 1.	Legal Proceedings	29
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3.	Defaults Upon Senior Securities	29
Item 4.	Mine Safety Disclosures	29
Item 5.	Other Information	29
Item 6.	Exhibits	30
	Signatures	31

Table of Contents PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

GENERAL CANNABIS CORP

CONDENSED CONSOLIDATED BALANCE SHEETS



		September 30, 2021
		(Unaudited)			December 31, 2020
Assets	****		****	****		****
Current assets
Cash and cash equivalents		$	2,459,453		$	750,218
Accounts receivable, net of allowance of $35,000 and $9,000, respectively			102,928			140,605
Current portion of notes receivable, net of allowance of $2,000 and $125,000, respectively			73,000			350,000
Inventories, net			885,583			371,799
Prepaid expenses and other current assets			185,323			225,122
Assets of discontinued operations - current portion			8,922			712,010
Total current assets			3,715,209			2,549,754

Right-of-use operating lease asset			2,487,930			1,836,455
Property and equipment, net			666,307			411,525
Investment, held for sale			—			208,761
Intangible assets, net			5,820,833			984,375
Goodwill			10,100,113			2,484,200
Assets of discontinued operations			—			43,697
Total assets		$	22,790,392		$	8,518,767

Liabilities and Stockholders' Equity

Current liabilities
Accounts payable and accrued expenses		$	856,935		$	1,344,269
Interest payable			444,752			16,790
Operating lease liability, current			587,291			370,800
Accrued stock payable			60,900			94,861
Warrant derivative liability			81,781			561,368
Notes payable - current			866,448			—
Liabilities of discontinued operations			114,363			742,064
Total current liabilities			3,012,470			3,130,152

Operating lease liability, non-current			1,968,569			1,499,280
Notes payable - long term (net of discount)			5,351,764			2,598,965
Related party long-term notes payable (net of discount)			284,183			289,579
Total liabilities			10,616,986			7,517,976
Commitments and contingencies (Note 9)			—			—

Stockholders’ equity
Preferred stock, no par value; 5,000,000 shares authorized; 1,180 and nil issued and outstanding, respectively			1,073,446			—
Common stock, $0.001 par value; 200,000,000 shares authorized; 84,713,865 shares and 60,813,673 shares issued and outstanding, respectively			84,711			60,813
Additional paid-in capital			91,029,601			75,891,414
Accumulated deficit			(80,014,352)			(74,951,436)
Total stockholders’ equity			12,173,406			1,000,791
Total liabilities and stockholders’ equity		$	22,790,392		$	8,518,767

See Notes to condensed consolidated financial statements.

Table of Contents GENERAL CANNABIS CORP

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	****	Three months ended				Nine months ended
		September 30,				September 30,
		2021		2020		2021		2020
Revenue	****
Retail sales		$	855,841	$	—	$	855,841	$	—
Cultivation sales			809,801		798,352		2,157,742		1,307,527
Interest			—		21,716		14,472		83,814
Total revenue			1,665,642		820,068		3,028,055		1,391,341

Costs and expenses
Cost of sales			1,473,209		304,031		2,539,840		585,274
Selling, general and administrative			672,981		751,211		1,853,731		2,464,476
Stock-based compensation			131,836		420,992		194,120		1,427,931
Professional fees			144,289		662,687		760,437		1,768,714
Depreciation and amortization			115,355		46,989		305,824		96,190
Total costs and expenses			2,537,670		2,185,910		5,653,952		6,342,585

Operating loss			(872,028)		(1,365,842)		(2,625,897)		(4,951,244)

Other expenses (income)
Amortization of debt discount and equity issuance costs			216,516		61,002		470,306		199,839
Interest expense			150,503		84,716		444,186		359,436
Loss on extinguishment of debt			233,374		—		233,374		1,186,336
(Gain) loss on derivative liability			(52,452)		(1,076,264)		1,043,531		(2,447,343)
Gain on sale of assets			(132,979)		—		(131,512)		(139,187)
Total other expenses (income), net			414,962		(930,546)		2,059,885		(840,919)

Net loss from continuing operations before income taxes			(1,286,990)		(435,296)		(4,685,782)		(4,110,325)

Loss from discontinued operations			(40,605)		(70,968)		(377,134)		(310,490)
Loss from operations before income taxes			(1,327,595)		(506,264)		(5,062,916)		(4,420,815)

Provision for income taxes			—		68,196		—		108,731
Net loss			(1,327,595)		(574,460)		(5,062,916)		(4,529,546)

Deemed dividend			—		—		—		(98,000)

Net loss attributable to common stockholders		$	(1,327,595)	$	(574,460)	$	(5,062,916)	$	(4,627,546)


Per share data - basic and diluted
Net loss from continuing operations per share		$	(0.02)	$	(0.01)	$	(0.07)	$	(0.09)
Net loss from discontinued operations per share		$	0.00	$	0.00	$	(0.01)	$	0.00
Net loss attributable to common stockholders per share		$	(0.02)	$	(0.01)	$	(0.08)	$	(0.10)
Weighted average number of common shares outstanding			69,122,293		58,097,819		64,381,989		47,951,618

See Notes to condensed consolidated financial statements.

Table of Contents GENERAL CANNABIS CORP

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine months ended September 30,
	2021			2020
Cash flows from operating activities		****	****		****
Net loss	$	(5,062,916)		$	(4,529,546)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and equity issuance costs		470,306			199,839
Depreciation and amortization		317,183			109,954
Amortization of loan origination fees		—			(6,667)
Loss on extinguishment of debt		233,374			1,186,336
Non-cash lease expense		364,520			150,984
Bad debt expense		(44,163)			128,491
Loss on disposal of property and equipment		1,467			8,593
Loss (gain) on warrant derivative liability		1,043,531			(2,447,343)
Stock-based compensation		194,120			1,427,931
Gain on sale of building		—			(139,187)
Changes in operating assets and liabilities, net of acquisitions
Accounts receivable		258,811			(28,941)
Prepaid expenses and other assets		559,073			(11,176)
Inventories		72,711			(100,144)
Accounts payable and accrued liabilities		(566,932)			(307,226)
Operating lease liabilities		(330,215)			(135,001)
Income taxes		—			108,731
Net cash used in operating activities:		(2,489,130)			(4,384,372)

Cash flows from investing activities
Purchase of property and equipment		(323,879)			(156,344)
Proceeds from sale of investment		208,761			—
Proceeds on notes receivable		433,393			—
Acquisition of Trees Colorado LLC		(1,122,015)			—
Net proceeds from sale of Next Big Crop		(132,979)			—
Proceeds from sale of building		—			1,421,134
Net cash (used in) provided by investing activities		(936,719)			1,264,790

Cash flows from financing activities
Proceeds from the sale of common stock and warrants - accrued stock payable		—			3,000,000
Proceeds from the exercise of warrants		—			90,000
Proceeds from exercise of stock options		194,634			—
Proceeds from preferred stock offering		1,180,000			—
Proceeds from notes payable		3,960,000			1,500,000
Payments on notes payable		(200,000)			(975,000)
Net cash provided by financing activities		5,134,634			3,615,000

Net increase in cash and cash equivalents		1,708,785			495,418
Cash and cash equivalents, beginning of period		755,769			224,994
Cash and cash equivalents, end of period	$	2,464,554		$	720,412

Supplemental schedule of cash flow information
Cash paid for interest	$	16,224		$	364,440

Non-cash investing & financing activities
Cashless warrant exercises	$	1,557,078		$	903,779
Beneficial conversion feature	$	1,110,039		$	233,500
10% Warrants recorded as a debt discount and additional paid-in capital	$	1,239,300		$	—
Issuance of common stock to a consultant	$	120,142		$	—
Operating lease right-of-use asset/operating lease liability	$	700,351		$	2,721,069
Deemed dividend from 8.5% warrant repricing	$	—		$	98,000
15% Warrants recorded as a debt discount and additional paid-in capital	$	—		$	167,163
15% Warrants recorded as a loss on extinguishment of debt and additional paid-in capital	$	—		$	668,336
Debt converted to equity	$	—		$	957,056
Issuance of common stock to an employee	$	—		$	100,000
Stock issued in connection with SevenFive Farm acquisition	$	—		$	2,861,495

See Notes to condensed consolidated financial statements.

Table of Contents GENERAL CANNABIS CORP

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES

IN STOCKHOLDERS’ EQUITY (DEFICIT)


	For the three months ended September 30, 2021
	Preferred Stock				Common Stock			Additional		Accumulated
	Shares	****	Amount		Shares	Amount		Paid-in Capital		Deficit		Total
July 1, 2021	—		$	—	62,266,275	$	62,264	$	80,140,373	$	(78,686,757)	$	1,515,880
Common stock issued upon exercise of stock options	—			—	33,140		33		12,892		—		12,925
Common stock issued to a consultant	—			—	34,140		34		20,108		—		20,142
Common stock issued for acquisition of Trees Colorado LLC	—			—	22,380,310		22,380		10,384,464		—		10,406,844
Preferred shares issued	1,180			1,073,446	—		—		—		—		1,073,446
Warrants issued with preferred stock	—			—	—		—		106,554		—		106,554
Modification of Warrants	—			—	—		—		233,374		—		233,374
Modification of Options	—			—	—		—		21,525		—		21,525
Stock-based compensation	—			—	—		—		110,311		—		110,311
Net loss	—			—	—		—		—		(1,327,595)		(1,327,595)
September 30, 2021	1,180		$	1,073,446	84,713,865	$	84,711	$	91,029,601	$	(80,014,352)	$	12,173,406

	For the three months ended September 30, 2020
	Preferred Stock				Common Stock			Additional		Accumulated
	Shares		Amount		Shares	Amount		Paid-in Capital		Deficit		Total
July 1, 2020	—		$	—	51,188,564	$	51,189	$	67,406,256	$	(71,226,830)	$	(3,769,385)
Sale of common stock, net of issuance costs	—			—	7,532,010		7,532		2,992,468		—		3,000,000
Stock option granted to employees and consultants	—			—	—		—		420,990		—		420,990
Net loss	—			—	—		—		—		(574,460)		(574,460)
September 30, 2020	—		$	—	58,720,574	$	58,721	$	70,819,714	$	(71,801,290)	$	(922,855)


	****	For the nine months ended September 30, 2021
		Preferred Stock				Common Stock					Additional			Accumulated
	****	Shares	****	Amount		Shares	****	Amount		****	Paid-in Capital		****	Deficit		****	Total
January 1, 2021		—		$	—	60,813,673		$	60,813		$	75,891,414		$	(74,951,436)		$	1,000,791
Common stock issued to consultants		—			—	146,499			146			119,996			—			120,142
Common stock issued upon exercise of stock options		—			—	366,760			367			194,267			—			194,634
Common stock issued for acquisition of Trees Colorado LLC		—			—	22,380,310			22,380			10,384,464			—			10,406,844
Warrants issued with 10% Notes		—			—	—			—			1,239,300			—			1,239,300
Beneficial conversion feature		—			—	—			—			1,110,039			—			1,110,039
Cashless exercise of warrants		—			—	1,006,623			1,005			1,556,073			—			1,557,078
Stock-based compensation		—			—	—			—			172,595			—			172,595
Preferred shares issued		1,180			1,073,446	—			—			—			—			1,073,446
Warrants issued with preferred stock		—			—	—			—			106,554			—			106,554
Modification of Warrants		—			—	—			—			233,374			—			233,374
Modification of Options		—			—	—			—			21,525			—			21,525
Net loss		—			—	—			—			—			(5,062,916)			(5,062,916)
September 30, 2021		1,180		$	1,073,446	84,713,865		$	84,711		$	91,029,601		$	(80,014,352)		$	12,173,406

		For the nine months ended September 30, 2020
		Preferred Stock				Common Stock					Additional			Accumulated
		Shares	****	Amount		Shares	****	Amount		****	Paid-in Capital		****	Deficit		****	Total
January 1, 2020		—		$	—	39,497,480		$	39,498		$	61,468,034		$	(67,271,744)		$	(5,764,212)
Sale of common stock, net of issuance costs		—			—	7,574,745			7,575			3,092,425			—			3,100,000
Common stock issued upon conversion of debt		—			—	2,215,892			2,215			954,841			—			957,056
Common stock issued for acquisition of SevenFive Farm		—			—	8,859,117			8,859			1,894,522			—			1,903,381
Stock options granted to employees and consultants		—			—	—			—			1,347,688			—			1,347,688
Beneficial conversion feature		—			—	—			—			233,500			—			233,500
Warrants exercised		—			—	200,000			200			172,041			—			172,241
Warrants issued with the 15% Notes		—			—	—			—			835,499			—			835,499
Cashless exercise of warrants		—			—	373,340			374			821,164			—			821,538
Net loss		—			—	—			—			—			(4,529,546)			(4,529,546)
September 30, 2020		—		$	—	58,720,574		$	58,721		$	70,819,714		$	(71,801,290)		$	(922,855)

See Notes to condensed consolidated financial statements.

Table of Contents GENERAL CANNABIS CORP

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. NATURE OF OPERATIONS, HISTORY AND PRESENTATION

Nature of Operations

General Cannabis Corp, a Colorado Corporation (the “Company,” “we,” “us,” or “our,”) (formerly, Advanced Cannabis Solutions, Inc.), was incorporated on June 3, 2013, and provides services and products to the regulated cannabis industry. We currently trade on the OTCQB® Market under the trading symbol CANN. As of September 30, 2021, our operations are segregated into the following segments:

Retail (“Retail Segment”)

Through our acquisition of TDM, LLC (“TREES Englewood”) in September 2021, we operate a retail dispensary store in Englewood, Colorado.

Cultivation (“Cultivation Segment”)

Through our acquisition of SevenFive Farm ("SevenFive") in May 2020, we operate a 17,000 square foot licensed light deprivation greenhouse cultivation facility.

During the three and nine months ended September 30, 2021, 24% and 12% of SevenFive’s revenue was with two and one customers, respectively.

Discontinued Operations - Operations Consulting and Products (“Operations Segment”)

Through Next Big Crop (“NBC”), we delivered comprehensive consulting services to the cannabis industry that included obtaining licenses, compliance, cultivation, retail operations, logistical support, facility design and construction, and expansion of existing operations.

NBC oversaw our wholesale equipment and supply business, operating under the name “GC Supply,” which provided turnkey sourcing and stocking services to cultivation, retail and infused products manufacturing facilities. Our products included building materials, equipment, consumables and compliance packaging. NBC also provided operational support for our internal cultivation. On July 16, 2021, we entered into an Asset Purchase Agreement with an individual to sell substantially all of the assets of NBC for a total of $150,000 and 10% of profits generated by the buyer in the states of Michigan, Mississippi, and Massachusetts for a period of twelve months from the closing. On August 2, 2021, the sale of NBC was completed.

Basis of Presentation

The accompanying condensed consolidated financial statements include all accounts of the Company and its wholly owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by accounting principles generally accepted in the United States of America ("U.S. GAAP") can be condensed or omitted. The condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and notes thereto of the Company for the year ended December 31, 2020, which were included in the annual report on Form 10-K filed by the Company on April 1, 2021. 7

Table of Contents In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and notes thereto of the Company and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of the Company's financial position and operating results. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the year ending December 31, 2021, or any other interim or future periods. Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies.

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Use of Estimates

The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Furthermore, when testing assets for impairment in future periods, if management uses different assumptions or if different conditions occur, impairment charges may result. In particular, the COVID-19 pandemic has adversely impacted and is likely to further adversely impact the Company's business and markets. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, reserves and allowances, fair value measurements and asset impairment charges, will depend on future developments that are highly uncertain and difficult to predict. These developments include, but are not limited to, the duration and spread of the pandemic, its severity in our markets and elsewhere, governmental actions to contain the spread of the pandemic and respond to the reduction in global economic activity, and how quickly and to what extent normal economic and operating conditions can resume.

Discontinued Operations

On January 1, 2021, we discontinued our investments segment. As this is not a materially significant segment, we have not shown the effects of the discontinued segment in the financial statements.

On December 26, 2019, the board of directors and management made the strategic decision to discontinue the operations for both the Security Segment and the Consumer Goods Segment. The assets and liabilities classified as discontinued operations for the Security Segment and Consumer Goods Segment are presented separately in the balance sheet and the operating results.

The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows. As of September 30, 2021, and December 31, 2020, there are $5,101 and $5,551, respectively, of cash and cash equivalents included in assets of discontinued operations on the balance sheet.

Going Concern

The Company incurred net losses of $1.3 million and $5.1 million in three and nine months ended September 30, 2021, respectively, and $0.6 million and $4.5 million for the three and nine months ended September 30, 2020, respectively, and had an accumulated deficit of $80 million as of September 30, 2021. The Company had cash and cash equivalents of $2.5 million and $0.8 million as of September 30, 2021 and December 31, 2020, respectively. 8

Table of Contents The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and has primarily funded its operations with proceeds from the issuance of convertible debt. The Company expects its operating losses to continue into the foreseeable future as it continues to execute its acquisition and growth strategy.

The Company believes that its cash and cash equivalents as of September 30, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of filing this Quarterly Report on Form 10-Q due to the receipt of an additional $2.3 million of cash in April 2021 from the issuance of a convertible note offering, the receipt of an additional $1.2 million of cash in September 2021 from the issuance of preferred stock and the pending acquisition of three dispensaries (See Note 13 for further information). The Company may need additional funding to support its planned investing activities. If the Company is unable to obtain additional funding, it would be forced to delay, reduce or eliminate some or all of its acquisition efforts, which could adversely affect its business prospects.

Summary of Significant Accounting Policies

See our Annual Report on Form 10-K for the year ended December 31, 2020, for discussion of the Company's significant accounting policies.

Recently Issued Accounting Standards

FASB ASU 2020-06 – “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”- In June 2020, the Financial Accounting Standards Board (“FASB”) issued guidance which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Accounting Standards Updates (“ASU”) also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation in certain areas. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2021, although early adoption is permitted. We are in the process of evaluating the impact of this new guidance on our consolidated financial statements.

FASB ASU 2019-12 – “Income Taxes (Topic 740)” – In December 2019, the FASB issued guidance which simplifies certain aspects of accounting for income taxes. The guidance is effective for interim and annual reporting periods beginning after December 15, 2020, and early adoption is permitted. We adopted this ASU in the first quarter of 2021. This ASU did not have a material effect on our condensed consolidated financial statements.

NOTE 2. BUSINESS ACQUISITION

On May 13, 2020, we received approval of the transaction and transfer of the Dalton Adventures, LLC (“Seller”) license from the Colorado Marijuana Enforcement Division. On May 25, 2020, we finalized the acquisition, pursuant to which we acquired the assets of the Seller that constitute the business of SevenFive Farm, a cultivation facility in Boulder, Colorado, whereby we acquired fixed assets, inventory, a cultivation license and the tradename. The purchase price paid by the Company to the Seller was 8,859,117 shares of common stock. The closing price of General Cannabis Corp’s common stock on May 13, 2020, the date of license transfer, was $0.38 per share, as such, fair value of consideration is $3,808,951. The purchase agreement had a provision whereby the Seller may require us to repurchase in cash 25% of the shares issued to the owner of Dalton Adventures, LLC at a repurchase price equal to the same volume weighted average price used to determine the number of shares issued to the owner of Dalton Adventures, LLC at closing. As a result, we recorded a liability using Black-Scholes in the amount of $442,487 and reduced additional paid-in capital. In December 2020, the Seller waived his right to this provision in the purchase agreement and no longer has the possibility of the buyback of the shares. Therefore, no stock put liability is recorded as of December 31, 2020 and the liability was reversed into equity. We completed the allocation of the purchase price in the first quarter of 2021. 9

Table of Contents The table below reflects the Company’s estimates of the acquisition date fair values of the assets acquired:


Inventories	$	185,261
Fixed assets		89,490
Tradename		1,050,000
Goodwill		10,100,113
	$	11,424,864

The accompanying condensed consolidated financial statements include the results of SevenFive from the date of acquisition for financial reporting purposes, May 13, 2020. The pro forma effects of the acquisition on the results of operations as if the transaction had been completed on January 1, 2020, are as follows:


	****	Three months ended		****	Nine months ended
		September 30,			September 30,
		2020			2020
Total revenues		$	1,585,564		$	4,986,077
Net loss attributable to common stockholders		$	(643,465)		$	(4,548,926)
Net loss per common share:		$	(0.01)		$	(0.09)
Weighted average number of basic and diluted common shares outstanding			58,097,819			52,704,502

The unaudited proforma results of operations are presented for information purposes only. The unaudited pro-forma results are not intended to present actual results that would have been attained had the acquisition been completed as of January 1, 2020, or to project potential operating results as of any future date or for any future periods.

On September 2, 2021, General Cannabis Corp. (the “Company”) completed the acquisition of substantially all of the assets of TREES Englewood, representing a portion of the overall Trees transaction (“Trees Transaction”) previously disclosed pursuant to that certain First Amended and Restated Agreement and Plan of Reorganization and Liquidation dated May 28, 2021 by and among the Company, seller and certain other sellers party thereto, that consists of the assets relating to the Trees dispensary located in Englewood, Colorado (“Englewood Closing”). The cash paid by the Company in connection with the Englewood Closing consisted of $1,155,256.09 and stock consideration of 22,380,310 shares of the Company’s Common Stock. Further, cash equal to $1,732,884.14 will be paid to the seller in equal monthly installments over a period of 24 months from the Englewood Closing.

The table below reflects the Company’s estimates of the acquisition date fair values of the assets acquired:


Cash	$	32,941
Fixed assets		59,335
Inventory		586,495
Tradename		5,000,000
Goodwill		7,615,913
	$	13,294,684

Table of Contents The accompanying condensed consolidated financial statements include the results of Trees Englewood from the date of acquisition for financial reporting purposes, September 2, 2021. The pro forma effects of the acquisition on the results of operations as if the transaction had been completed on January 1, 2020, are as follows:


	****	Three months ended				****	Nine months ended
		September 30,					September 30,
		2021		2020			2021		2020
Total revenues		$	2,766,183	$	3,757,751		$	8,847,507	$	10,086,668
Net income (loss) attributable to common stockholders		$	254,862	$	(90,229)		$	749,341	$	847,567
Net income (loss) per common share		$	0.00	$	(0.00)		$	0.01	$	0.01
Weighted average number of basic and diluted common shares outstanding			84,691,204		80,478,129			84,384,904		70,331,928

NOTE 3. DISCONTINUED OPERATIONS ****

On July 16, 2021, we entered into an Asset Purchase Agreement with an individual to sell substantially all of the assets of NBC for a total of $150,000 and 10% of profits generated by the buyer in the states of Michigan, Mississippi, and Massachusetts for a period of twelve months from the closing. On August 2, 2021, the sale of NBC was completed. The condensed consolidated balance sheets include 2019 discontinued operations cash balances of $5,101 and $5,551 as of September 30, 2021 and December 31, 2020, respectively, and accounts payable balances of $53,128 and $54,641 as of September 30, 2021 and December 31, 2020, respectively. The below table does not include the 2019 discontinued operations.

Assets and liabilities of discontinued operations for the Operations Segment included the following:


	September 30,		December 31,
	2021		2020
Accounts receivable, net	$	3,821	$	187,185
Prepaid expenses and other current assets		—		519,274
Current assets discontinued operations		3,821		706,459

Property and equipment, net		—		43,697
Noncurrent assets discontinued operations		—		43,697

Accounts payable and accrued expenses		21,235		169,492
Customer deposits		40,000		517,931
Current liabilities discontinued operations	$	61,235	$	687,423

Table of Contents A summary of the discontinued operations for the Operations Segment is presented as follows:


		Three months ended						Nine months ended
		September 30,						September 30,
	****	2021		****	2020		****	2021		****	2020
Product revenues		$	463		$	632,623		$	614,764		$	3,099,113
Service revenues			4,116			132,873			523,994			495,623
Total revenues			4,579			765,496			1,138,758			3,594,736

Cost of sales			29,480			685,885			1,157,035			3,140,326
Selling, general and administrative			12,721			205,363			342,554			658,720
Professional fees			143			10,300			4,944			15,970
Depreciation and amortization			2,840			3,921			11,359			11,590
Total costs and expenses			45,184			905,469			1,515,892			3,826,606
Loss from discontinued operations		$	(40,605)		$	(139,973)		$	(377,134)		$	(231,870)

The condensed consolidated statement of operations include 2019 discontinued operations gain of $69,005 and loss of $78,620 for the three and nine months ended September 30, 2020, respectively, and are not reflected in the above table.

The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows. The following table provides selected information on cash flows related to discontinued operations for the Operations Segment for the nine months ended September 30, 2021 and 2020.


		Nine months ended
		September 30,
	****	2021		****	2020
Accounts receivables		$	183,364		$	(18,344)
Prepaid expenses and other current assets			519,274			83,168
Depreciation and amortization			11,359			11,590
Capital expenditures			—			(6,696)
Accounts payable and accrued expenses			(148,257)			(12,394)
Customer deposits			(477,931)			(259,862)

NOTE 4. INVENTORIES, NET

Our inventories consisted of the following:


		September 30,			December 31,
	****	2021		****	2020
Raw materials		$	46,411		$	8,137
Work-in-progress and finished goods			839,172			363,662
Less: Inventory reserves			—			—
Inventories, net		$	885,583		$	371,799

NOTE 5. LEASES

On May 13, 2020, we entered into a commercial real estate lease with a related party (see Note 11) for 17,000 square feet of greenhouse space in Boulder, CO, with an initial term of five years and, at our option, two additional terms of five years each. Rent is $30,900 per month with 1.5% annual escalations. We also pay our portion of real estate taxes. In December 2020, we amended the lease to include a 3% rent escalation in 2021 and 2022. No other changes to the lease were made. We accounted for the amendment as a lease modification and remeasured the lease with an incremental borrowing rate of 20% which resulted in an increase of $246,250 to the right-of-use operating lease asset and lease liability from the initial lease valued on May 13, 2020 using an incremental borrowing rate of 22.8%. We determined the present value of the future lease payments using a discount rate of 20% over a 15 year term, our incremental borrowing 12

Table of Contents rate based on outstanding debt, resulting in a right-of-use asset and lease liability of $1,877,423 which are being applied ratably over the term of the lease. As of September 30, 2021, the balance of the right-of-use asset and lease liability was $1,806,784 and $1,872,659, respectively.

On September 2, 2021, we entered into a commercial real estate lease with a related party (see Note 11) for retail space in Englewood, CO, with an initial term of five years and, at our option, two additional terms of three years each. Rent is $10,000 per month with 3% annual escalations during the initial term and 4% annual escalations during the option term. We also pay our portion of real estate taxes. We determined the present value of the future lease payments using a discount rate of 20% over a 11 year term, resulting in a right-of-use asset and lease liability of $602,140 which are being applied ratably over the term of the lease. As of September 30, 2021, the balance of the right-of-use asset and lease liability was $590,270 and $592,140, respectively.

Through the acquisition of Trees Englewood, we entered into a commercial real estate lease for office space in Denver, CO. This office space is our new principal business office. The lease has 15 months remaining. Rent is $7,150 per month with a 3% escalation beginning in November 2021. We also pay our portion of real estate taxes. We determined the present value of the future lease payments using a discount rate of 20% over a 15 month term, resulting in a right-of-use asset and lease liability of $98,211 which are being applied ratably over the term of the lease. As of September 30, 2021, the balance of the right-of-use asset and lease liability was $90,876 and $91,061, respectively.

Future remaining minimum lease payments were as follows:


Year ending December 31,	****	Amount
2021 (remaining six months)		$	144,577
2022			583,822
2023			512,180
2024			521,731
2025			531,481
Thereafter			5,081,765
Total			7,375,556
Less: Present value adjustment			(4,819,696)
Operating lease liability		$	2,555,860

NOTE 6. ACCRUED STOCK PAYABLE

The following tables summarize the changes in accrued common stock payable:


					Number of
	****	Amount		****	Shares
Balance as of December 31, 2020		$	94,861			359,415
Stock issued			(33,961)			(259,415)
Balance as of September 30, 2021		$	60,900			100,000

In December 2020, several warrant holders exercised their 2020 A warrants through cashless exercises, and we issued 282,213 shares of common stock. 259,415 of those shares issued had not been transferred to the warrant holders as of December 31, 2020 and were included in accrued stock. During January 2021 all shares were issued. See Note 8 for further details of the cashless exercises. 13

Table of Contents NOTE 7. NOTES PAYABLE

Our notes payable consisted of the following:


	****	September 30,		****	December 31,
		2021			2020
2020 10% Notes		$	6,580,000		$	2,600,000
2019 15% Notes			—			200,000
Related party note payable			320,000			340,000
Trees Acquisition Note			1,732,884			—
Unamortized debt discount			(2,130,489)			(251,456)
			6,502,395			2,888,544
Less: Current portion			(866,448)			—
Long-term portion		$	5,635,947		$	2,888,544

10% Notes

In December 2020, we entered into a Securities Purchase Agreement (the “Securities Purchase Agreement’) with certain accredited investors (the “10% Investors”), pursuant to which we issued and sold senior convertible promissory notes (the “10% Notes”) with an aggregate principal amount of $2,940,000 in exchange for payment to us by certain 10% Investors of an aggregate amount of $1,940,000 in cash, as well as cancellation of outstanding indebtedness of the 15% Notes (defined below) in the aggregate amount of $1,000,000. In connection with the issuance of the 10% Notes, the holders of the 10% Notes received warrants (the “10% Warrants”) to purchase shares of our common stock equal to 20% coverage of the aggregate principal amount at $0.56 per share. In the aggregate, this equals 1,050,011 shares of our common stock. The 10% Notes bear interest at an annual rate of 10% and will mature on December 23, 2023. The 10% Investors have the option at any time to convert up to 50% of the outstanding unpaid principal and accrued interest of the 10% Notes into Common Stock at a variable price of 80% of the market price but no less than $0.65 per share and no more than $1.00 per share. The 10% Warrants are exercisable at an exercise price of $0.56 per warrant.

The relative fair value of the new funding on the 10% Warrants was recorded as a debt discount and additional paid-in capital of $254,400. The relative fair value of the cancellation of the outstanding indebtedness was recorded as an extinguishment of debt and additional paid-in capital of $131,000. We recorded amortization of debt discount expense from the 10% Notes of $21,868 and nil for the three months ended September 30, 2021 and 2020, respectively, and $64,891 and nil during the nine months ended September 30, 2021 and 2020, respectively. We determined there was no beneficial conversion feature on the 10% Notes issued in December 2020. The 10% Notes are treated as conventional debt.

For purposes of determining the debt discount, the underlying assumptions used in the binomial lattice model to determine the fair value of the 10% Warrants as of December 23, 2020, were:


Current stock price	$	0.53
Exercise price	$	0.56
Risk-free interest rate		0.38 %
Expected dividend yield		—
Expected term (in years)		5.0
Expected volatility		115%

On February 8, 2021, we entered into a Securities Purchase Agreement with an accredited 10% Investor, pursuant to which we issued and sold 10% Notes with an aggregate principal amount of $1,660,000 to such 10% Investor. The 10% Notes are part of an over-allotment option exercised by us in connection with the convertible note offering consummated on December 23, 2020, as discussed above. In connection with the issuance of the 10% Notes, the holder received warrants to purchase shares of our common stock equal to 20% coverage of the aggregate principal amount at $0.56 per share. In the aggregate, this equals 592,858 shares of our common stock with a par value $0.001 per share. The 10% Notes bear interest at an annual rate of 10% and will mature on February 8, 2024. The 10% Investor has the option to convert up to 50% of the outstanding unpaid principal and accrued interest of the 10% Notes into Common Stock at a 14

Table of Contents variable price of 80% of the market price but no less than $0.65 per share and no more than $1.00 per share. The 10% Warrants are exercisable at an exercise price of $0.56 per warrant.

The relative fair value of the new funding on the 10% Warrants was recorded as a debt discount and additional paid-in capital of $429,300. We determined that this 10% Note had a beneficial conversion feature and is calculated at its intrinsic value (that is, the difference between the effective conversion price of $0.66 at the date of the note issuance and the fair value of the common stock into which the debt is convertible at the commitment date, per share being $0.90, multiplied by the number of shares into which the debt is convertible). The valuation of the beneficial conversion feature recorded cannot be greater than the face value of the note issued. We recorded $417,539 as additional paid in capital and a debt discount and included in our consolidated statement of operations. We recorded amortization of debt discount expense from the 10% Notes issued in February 2021 of $71,150 and nil for the three months ended September 30, 2021 and 2020, respectively, and $180,968 and nil during the nine months ended September 30, 2021 and 2020, respectively. The 10% Notes are treated as conventional debt.

For purposes of determining the debt discount, the underlying assumptions used in the binomial lattice model to determine the fair value of the 10% Warrants as of February 8, 2021, were:


Current stock price	$	1.12
Exercise price	$	0.56
Risk-free interest rate		0.48 %
Expected dividend yield		—
Expected term (in years)		5.0
Expected volatility		118%

On April 20, 2021, we entered into a Securities Purchase Agreement with accredited 10% Investors, pursuant to which we issued and sold 10% Notes with an aggregate principal amount of $2,300,000 to such 10% Investors. The 10% Notes are part of an over-allotment approved by the existing noteholders in connection with the original convertible note offering of $4,600,000 consummated on December 23, 2020 and February 8, 2021. In connection with the issuance of the 10% Notes, each holder received warrants to purchase shares of our common stock equal to 20% coverage of the aggregate principal amount at $0.56 per share, except that the warrants coverage to one Investor acting as lead investor in the raise received approximately 35.5% of the aggregate principal amount invested. The 10% Notes bear interest at an annual rate of 10% and will mature on April 20, 2024. The 10% Investors have the option to convert up to 50% of the outstanding unpaid principal and accrued interest of the 10% Notes into Common Stock at a variable price of 80% of the market price but no less than $0.65 per share and no more than $1.00 per share. The 10% Warrants are exercisable at an exercise price of $0.56 per warrant.

The relative fair value of the new funding on the 10% Warrants was recorded as a debt discount and additional paid-in capital of $810,000. We determined that these 10% Notes had a beneficial conversion feature and is calculated at its intrinsic value (that is, the difference between the effective conversion price of $0.49 at the date of the note issuance and the fair value of the common stock into which the debt is convertible at the commitment date, per share being $0.83, multiplied by the number of shares into which the debt is convertible). The valuation of the beneficial conversion feature recorded cannot be greater than the face value of the note issued. We recorded $692,500 as additional paid in capital and a debt discount and included in our consolidated statement of operations. We recorded amortization of debt discount expense from the 10% Notes issued in April 2021 of $126,025 and nil for the three months ended September 30, 2021 and 2020, respectively, and $224,446 and nil during the nine months ended September 30, 2021 and 2020, respectively. The 10% Notes are treated as conventional debt. 15

Table of Contents For purposes of determining the debt discount, the underlying assumptions used in the binomial lattice model to determine the fair value of the 10% Warrants as of April 20, 2021, were:


Current stock price	$	0.83
Exercise price	$	0.56
Risk-free interest rate		0.81%
Expected dividend yield		—
Expected term (in years)		5.0
Expected volatility		115%

15% Notes

In December 2019, we completed a private placement with certain accredited investors pursuant to an unsecured promissory note (the “15% Notes”) with an aggregate principal amount of $300,000. In February and March 2020, we completed private placements with certain accredited investors, including some holders of our 2019 12% Notes (as defined below), of 15% Notes with an aggregate principal amount of $2,031,000 in exchange for $525,000 of new funding and the cancellation of $1,506,000 aggregate principal amount of the 2019 12% Notes. The 15% Notes have an annual interest rate of 15% and matured on January 31, 2021. $1.0 million of the 15% Notes were exchanged for the 10% Notes (see above), $2.1 million was paid in full in December 2020 and the remaining $200,000 was paid in full in the first quarter 2021. The 15% Notes provide that they shall be repaid in full out of the proceeds of any new debt or equity capital raise with net proceeds of more than $5,000,000. In connection with the issuance of the 15% Notes, each holder of 15% Notes received three warrants (i.e., a 2020 A Warrant, a 2020 B Warrant and a 2020 C Warrant) to acquire shares of common stock at an exercise price equal to $0.45 per share, with the number of shares subject to each warrant equal to one share for each $1.00 of principal amount of 15% Notes issued to the noteholder. The 2020 A Warrants had an expiration date of December 31, 2020, the 2020 B Warrants have an expiration date of December 31, 2021, and the 2020 C Warrants have an expiration date of December 31, 2022 (collectively, the “15% Warrants”). By way of example, if an investor was issued a 15% Note with a principal amount of $250,000, such noteholder would receive a 2020 A Warrant to purchase 250,000 shares of common stock, a 2020 B Warrant to purchase 250,000 shares of common stock and a 2020 C Warrant to purchase 250,000 shares of common stock. Accordingly, the Company issued 15% Warrants to purchase a total of 6,993,000 shares of common stock to the holders of 15% Notes. The exercise price of these warrants is subject to adjustment as a result of certain future equity issuances of securities by the Company at a price below the then-effective exercise price of the 15% Warrants. As a result of such subsequent issuances of securities by the Company during the second quarter of 2020, the exercise price of the 15% Warrants had decreased to $0.3983 per share. As of September 30, 2021, the warrant holders exercised 1,131,000 of the 2020 A Warrants into 282,813 shares of our common stock through cashless exercise.

We received $300,000 of cash in December 2019 and an additional $525,000 of cash January 2020 through March 2020 for issuing the 15% Notes. The relative fair value of the new funding on the 15% Warrants was recorded as a debt discount and additional paid-in capital of $333,056. The relative fair value of the cancellation of the outstanding indebtedness was recorded as an extinguishment of debt and additional paid-in capital of $668,335. We recorded amortization of debt discount expense from the 15% Notes of nil and $61,002 for the three months ended September 30, 2021 and 2020, respectively, and nil and $199,839 during the nine months ended September 30, 2021 and 2020, respectively. The 15% Notes are otherwise treated as conventional debt.

For purposes of determining the debt discount, the underlying assumptions used in the binomial lattice model to determine the fair value of the 15% Warrants as of March 2020 were:


Current stock price	$	0.45 - 0.67
Exercise price	$	0.45
Risk-free interest rate		0.68 - 1.62 %
Expected dividend yield		—
Expected term (in years)		0.83 - 3.06
Expected volatility		112 - 119 %

Table of Contents On September 17, 2021 we entered into warrant amendments with certain ‘A’ and ‘B’ warrant holders from the 15% Notes. Pursuant to the warrant amendment the expiration date was extended until December 31, 2024 and the exercise price thereof was increased to $1.00 per warrant share. Warrant amendments were entered into with warrant holders representing an aggregate of 400,000 A warrants and 1,211,000 B warrants. We recognized an additional expense of $233,374 in loss on extinguishment of debt as a result of the modification.

NOTE 8. WARRANT DERIVATIVE LIABILITY

On May 31, 2019 we received gross proceeds of $3 million by issuing three million shares of our common stock and three million warrants (“2019 Warrants”) to purchase shares of our common stock (“2019 Units”) in a registered direct offering for $1.00 per 2019 Unit (collectively defined as the “2019 Capital Raise”). The 2019 Warrants, issued with the 2019 Capital Raise, are accounted for as a derivative liability. The 2019 Warrant agreements contain a cash settlement provision whereby the holders could settle the warrants for cash based on the Black-Scholes value, upon certain fundamental transactions, as defined in the 2019 Warrant agreement, that are considered outside of the control of management, such as a change of control. The original exercise price of the 2019 Warrants was $1.30 per share. The 2019 Warrants contain certain anti-dilution adjustment provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrants. As a result of such subsequent issuances of securities by the Company during the fourth quarter 2019, the exercise price of the 2019 Warrants decreased to $0.45 per share and the number of shares subject to the 2019 Warrants increased to 8,666,666 shares of common stock as of December 31, 2019. In May 2020, we issued securities at a price lower than the $0.45 per share above. As a result, the exercise price of the 2019 Warrants decreased to $0.3983 per share and the number of shares subject to the 2019 Warrants increased to 9,591,614 shares of common stock.

During the first quarter of 2021 the warrant holders exercised 1,323,000 warrants into 747,208 shares of our common stock through cashless exercise. We booked an adjustment to the derivative liability of $1,523,117 as a result. As of September 30, 2021, there were 322,807 of the 2019 Warrants outstanding.

The following are the key assumptions that were used to determine the fair value of the 2019 Warrants


	May 31,			December 31,			September 30,		****
	2019			2020			2021		****
Number of shares underlying the warrants		3,000,000			1,645,807			322,807
Fair market value of stock	$	0.95		$	0.48		$	0.41
Exercise price	$	1.30		$	0.3983		$	0.3983
Volatility		133	%		108	%		105	%
Risk-free interest rate		1.93	%		0.36	%		0.98	%
Warrant life (years)		5.00			3.41			2.66

The following table sets forth a summary of the changes in the fair value of the warrant derivative liability, our Level 3 financial liabilities that are measured at fair value on a recurring basis:


	Nine months ended September 30,
	2021		2020
Beginning balance	$	561,368	$	4,620,593
Warrant exercise		(1,523,118)		(82,241)
Change in fair value of warrants derivative liability		1,043,531		(1,375,619)
Ending balance	$	81,781	$	3,162,733

NOTE 9. COMMITMENTS AND CONTINGENCIES

Table of Contents result of the COVID-19 pandemic. The lease contains a ‘force majeure’ clause which includes a provision that neither party is liable for failure to perform its obligations under the lease which have become practicably impossible because of circumstances beyond the reasonable control of the applicable party, including ‘pandemics or outbreak of communicable disease.’

The Company has taken the position that its failure to take possession and make any further payments under the lease is directly related to the COVID-19 pandemic. The Company intends to vigorously defend this action and believes that the above-referenced force majeure clause presents a complete defense to Plaintiff’s claims. Both parties have filed motions for summary judgment, and the parties are currently awaiting the decision of the court in respect thereof.

In June 2020, Michael Feinsod resigned as our Executive Chairman, claiming that his resignation was for "Good Reason" under the terms of his employment agreement. If it is ultimately determined that his resignation was, in fact, for "Good Reason", rather than a voluntary act absent "Good Reason", it could enable certain potential claims for benefits under his employment agreement, including potential claims for severance, for the vesting of his unvested options and/or for the extension of the term within which he can exercise his options in the future. Having reviewed the matter, however, we do not believe that Mr. Feinsod's resignation was for "Good Reason". Accordingly, we believe that Mr. Feinsod's resignation was voluntary, and that any such potential claims, if asserted, would be without foundation. Although the outcome of legal proceedings is subject to uncertainty, the Company will vigorously defend any future claims made by Mr. Feinsod alleging a "Good Reason" resignation.

From time to time, the Company is a party to various litigation matters incidental to the conduct of its business. The Company is not presently a party to any legal proceedings that would have a material adverse effect on its business, operating results, financial condition or cash flows.

NOTE 10. STOCKHOLDERS’ EQUITY

2021 Preferred stock offering

On September 10, 2021, we entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with various accredited investors (the “2021 Investors), pursuant to which we issued and sold Units consisting of Series A Convertible Preferred Stock (“Series A Preferred”) and warrants (the “Preferred Warrants”) to purchase shares of our common stock with a par value of $0.001 per share. The total number of Units sold was 1,180. Each Unit consists of one share of Series A Preferred and 354,000 Preferred Warrants. The purchase price of each Unit was $1,000, for an aggregate amount sold of $1,180,000. Each share of Series A Preferred is convertible into 1,000 shares of common stock upon the consummation of a capital raise of not less than $5,000,000. The Certificate of Designation of the Series A Preferred Stock (“Certificate of Designation”) was filed with the Secretary of the State of Colorado on September 14, 2021. The Certificate of Designations established the new preferred series entitled “Series A Convertible Preferred Stock” with no par value pers share, and sets forth the rights, restrictions, preferences and privileges of the Series A Preferred, summarized as follows:

●	Authorized Number of Shares – 5,000
●	Voting Rights – None
---	---
●	Dividends – 6% per annum, ‘paid in kind’ in shares of Series A Preferred
---	---
●	Conversion – Each share of Series A Preferred is mandatorily convertible into 1,000 shares of common stock upon a minimum capital raise of $5,000,000; sale, merger or business combination of the Company; or the Company listing on an exchange
---	---
●	Redemption – No rights of redemption by 2021 Investors, nor mandatory redemption
---	---

Table of Contents The Preferred Warrants have a five year term and an exercise price per Preferred Warrant share of $1.05. The warrants contain an anti-dilution provision pursuant to which upon we do a future capital raise at less than $1.00 per shares, each Preferred Investor will be granted additional Preferred Warrants on a ‘full-ratchet’ basis.

The proceeds received in the sale of the Series A Preferred totaled $1,180,000, for the issuance of 1,180 Series A Preferred, plus 354,000 warrants. The warrants were valued using a Black Scholes model, at $117,131 and per the relative fair value allocation, $1,073,446 was allocated to the Series A proceeds.

2020 Capital Raise

On May 29, 2020, we entered into a subscription agreement, as amended with Hershey Strategic Capital, LP and Shore Ventures III, LP (collectively as the “Hershey Investor”) with respect to the sale of shares of common stock and warrants to purchase common stock (collectively, the “securities”). The sales of the securities to the Hershey Investor consists of a minimum of $2,185,000 of securities and a maximum of $3,000,000 of securities, as described further below. The purchase price of the securities at each closing is as follows: (i) the purchase price of each share of common stock is $0.3983 per share, and (ii) for each one dollar invested by the Hershey Investor, the Hershey Investor receives a warrant to purchase a number of shares of common stock equal to 75% of the number of shares of common stock purchased by the Hershey Investor at an exercise price per share equal to $0.5565. The warrants have a term of five years. During the year ended December 31, 2020, we sold $3,000,000 of securities to the Hershey Investor, representing 7,532,010 shares of common stock and warrants to purchase 5,649,007 shares of common stock at an exercise price of $0.5565 per share. The warrants were recorded as equity and equity issuance costs in the amount of $2,173,074. Notwithstanding the foregoing, none of the Hershey Investor warrants are exercisable if after giving effect to such exercise the Hershey Investor (together with affiliates) would own in excess of 9.99% (“Beneficial Ownership Limitation”) of the shares of issued and outstanding Common Stock of the Company. The Beneficial Ownership Limitation may be increased by the Hershey Investor upon not less than 61 days’ prior notice.

The Hershey Subscription Agreement also provides the Hershey Investor with certain participation rights in future financings of the Company until the one-year anniversary of the second closing. The Hershey Subscription Agreement further provides that the Company shall, during a negotiation period ending October 4, 2020, endeavor to cause the existing holders of the promissory notes of the Company having an outstanding balance in the amount of approximately $2,331,000 as of June 1, 2020 that are due on or about January 31, 2021, to extend the maturity date of such notes to a date that is not earlier than January 31, 2022. As of October 4, 2020, $600,000 of the $2,331,000 outstanding notes had extended the maturity date. If, at the end of the negotiation period per the contract, all of the existing notes have not been amended to extend the maturity dates thereof, then the Company shall issue to the Hershey Investor additional warrants to purchase shares of common stock. Any such additional warrants will be for a number of shares of common stock based on the dollar amount of the outstanding balance of the existing notes that were not extended, with each one dollar of existing notes that were not extended representing one share subject to such additional warrant. The exercise price of any such additional warrants will be equal to 100% of the 30-day volume weighted average price of the Company’s common stock on the last day of the negotiation period, provided that such exercise price shall not be lower than $0.45 per share nor higher than $0.56 per share. The Hershey Investor extended the negotiation period to December 11, 2020. As of December 11, 2020, no existing holders had extended their promissory notes, therefore, we issued the Hershey Investor additional warrants in accordance with the agreement. On December 14, 2020 we issued an additional 1,631,000 warrants to purchase common stock at an exercise price of $0.4917 to the Hershey Investor. These warrants expire on December 11, 2025. The warrants were recorded as a deemed dividend in the amount of $732,494.

Stock-based compensation

We use the fair value method to account for stock-based compensation. We recorded $131,836 and $420,990 in compensation expense for the three months ended September 30, 2021 and 2020, respectively, and $194,120 and $1,427,931, for the nine months ended September 30, 2021 and 2020, respectively. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current period as well as options issued in the current period. Forfeited options result in a reversal in the period forfeited. The fair value of these instruments was calculated using the Black-Scholes option pricing method. 19

Table of Contents On September 3, 2021 we modified two employees stock options in conjunction with revised employment agreements. As a result of the modification, we recognized $21,525 in compensation expense for the three and nine months ended September 30, 2021 and 2020.

During the nine months ended September 30, 2021 we granted options to purchase 1,070,500 common shares to employees and directors. The options expire five years from the date of grant and vest over a period of one year. Fair value of the awards at the date of grants totaled $616,675.

The following summarizes Employee Awards activity:


				Weighted-
		Weighted-		Average
		Average		Remaining
	Number of	Exercise Price		Contractual	Aggregate
	Shares	per Share		Term (in years)	Intrinsic Value
Outstanding as of December 31, 2020	7,266,420	$	1.03	5.5	$	167,000
Granted	1,070,500		0.87
Exercised	(366,760)		0.53
Forfeited or expired	(1,902,800)		0.81
Outstanding as of September 30, 2021	6,067,360	$	1.13	5.1	$	81,000

Exercisable as of September 30, 2021	4,962,480	$	1.22	5.3	$	40,000

As of September 30, 2021, there was approximately $241,412 of total unrecognized compensation expense related to unvested employee awards, which is expected to be recognized over a weighted-average period of eleven months.

NOTE 11. RELATED PARTY TRANSACTIONS

On June 3, 2020, the Company entered into a consulting agreement with Adam Hershey, Interim Chief Executive Officer, board member and investor, pursuant to which he would act as a strategic consultant for the Company, including providing assistance with the sourcing and evaluation of merger and acquisition deals, strategic capital and strategic partnerships or joint ventures. Mr. Hershey is paid an initial monthly rate of $8,333 for the services, subject to certain adjustments. We paid $24,999 for the three months ended September 30, 2021 and 2020, respectively, and $74,997 and $33,332 for the nine months ended September 30, 2021 and 2020, respectively.

We currently have a lease agreement with Dalton Adventures, LLC in which we rent 17,000 square feet of greenhouse space in Boulder, Colorado for $34,636 a month, of which $30,900 is base rent and $3,736 is property taxes. The owner of Dalton Adventures, LLC is a principal shareholder and board member of the Company. We incurred approximately $115,000 and $101,000 for the three months ended September 30, 2021 and 2020, respectively, and $344,000 and $182,000 for the nine months ended September 30, 2021 and 2020.

We currently have a lease agreement with Bellewood Holdings, LLC in which we rent retail space for the Trees Englewood retail store in Englewood, Colorado for $10,000 per month. The owner of Bellewood Holdings, LLC is a principal shareholder and board member of the Company. We incurred approximately $11,871 of rent expense for the three and nine months ended September 30, 2021.

On December 23, 2020, four of our current board members purchased senior convertible promissory notes from the Company for an aggregate amount of $320,000. A board member who resigned in May 2021 purchased $30,000 of the senior convertible promissory notes from the Company. These notes are included in the 10% Notes discussed in Note 7. Accrued interest earned and owed to the board members was $25,257 as of September 30, 2021. 20

Table of Contents NOTE 12. SEGMENT INFORMATION

Our operations are organized into two segments: Retail and Cultivation. All revenue originates, and all assets are located in the United States. Segment information is presented in accordance with ASC 280, "Segments Reporting." This standard is based on a management approach that requires segmentation based upon the Company’s internal organization and disclosure of revenue and certain expenses based upon internal accounting methods. The Company’s financial reporting systems present various data for management to run the business, including internal profit and loss statements prepared on a basis not consistent with GAAP. The following information is presented net of discontinued operations.

Three months ended September 30


2021	Retail		Cultivation		Eliminations		Total
Revenues	$	855,841	$	835,719	$	(25,918)	$	1,665,642
Costs and expenses		(891,126)		(865,490)		9,048		(1,747,568)
Segment operating income	$	(35,285)	$	(29,771)	$	(16,870)		(81,926)
Corporate expenses								(1,205,064)
Net loss from continuing operations before income taxes							$	(1,286,990)


2020	Cultivation		Total
Revenues	$	798,352	$	798,352
Costs and expenses		(609,381)		(609,381)
Segment operating income	$	188,971		188,971
Corporate expenses				(624,267)
Net loss from continuing operations before income taxes			$	(435,296)

Nine months ended September 30


2021	****	Retail		****	Cultivation		****	Eliminations		****	Total
Total revenues		$	855,841		$	2,183,660		$	(25,918)		$	3,013,583
Costs and expenses			(891,126)			(2,340,913)			25,918			(3,206,121)
Operating (loss) income		$	(35,285)		$	(157,253)		$	—			(192,538)
Corporate expenses												(4,493,244)
Net loss from continuing operations before income taxes											$	(4,685,782)


2020	****	Cultivation		****	Total
Total revenues		$	1,307,527		$	1,307,527
Costs and expenses			(1,025,507)			(1,025,507)
Operating income		$	282,020			282,020
Corporate expenses						(4,392,345)
Net loss from continuing operations before income taxes					$	(4,110,325)


		September 30,			December 31,
Total assets	****	2021		****	2020
Retail		$	13,958,309		$	—
Cultivation			6,464,607			6,208,222
Corporate			2,363,655			1,567,021
Discontinued operations			3,821			755,707
Total assets - segments			22,790,392			8,530,950
Intercompany eliminations			—			(12,183)
Total assets - consolidated		$	22,790,392		$	8,518,767

Table of Contents NOTE 13. SUBSEQUENT EVENTS

On November 1, 2021, we moved our principal corporate headquarters to the lease acquired through the Trees acquisition. The new corporate address is 1901 S Navajo Street, Denver, Colorado, 80223. (See Note 5 for information regarding the lease).

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis (“MD&A”) is intended to provide an understanding of our financial condition, results of operations and cash flows by focusing on changes in certain key measures from year to year. This discussion should be read in conjunction with the Condensed Consolidated Unaudited Financial Statements contained in this Quarterly Report on Form 10-Q and the Consolidated Financial Statements and related notes and MD&A appearing in our Annual Report on Form 10-K as of and for the year ended December 31, 2020, as amended. The results of operations for an interim period may not give a true indication of results for future interim periods or for the year.

Cautionary Statement Regarding Forward Looking Statements

This Quarterly Report on Form 10-Q, including the financial statements and related notes, contains forward-looking statements that discuss, among other things, future expectations and projections regarding future developments, operations and financial conditions. All forward-looking statements are based on management’s existing beliefs about present and future events outside of management’s control and on assumptions that may prove to be incorrect. If any underlying assumptions prove incorrect, our actual results may vary materially from those anticipated, estimated, projected or intended. We undertake no obligation to publicly update or revise any forward-looking statements to reflect actual results, changes in expectations or events or circumstances after the date of this Quarterly Report on Form 10-Q.

When this report uses the words “we,” “us,” or “our,” and the “Company,” they refer to General Cannabis Corp (formerly, “Advanced Cannabis Solutions, Inc.”).

Our Products, Services and Customers

Through our two reporting segments, Retail and Cultivation, we provide products to the regulated cannabis industry, which include the following:

Retail (“Retail Segment”)

Through our acquisition of TDM, LLC (“TREES Englewood”), we operate a retail dispensary store in Englewood, Colorado.

Cultivation (“Cultivation Segment”)

Through SevenFive Farm (“SevenFive”), we operate a 17,000 square foot licensed light deprivation greenhouse cultivation facility. We believe our production capability is sufficient to meet the diverse needs of our recreational consumers in Colorado, from cost-effective, high-yield inputs to sophisticated and dried cannabis flower.

During the three and nine months ended September 30, 2021, 24% and 12% of SevenFive’s revenue was with two and one customer, respectively.

Discontinued Operations - Operations Consulting and Products

Through Next Big Crop (“NBC”), we deliver comprehensive consulting services to the cannabis industry that include obtaining licenses, compliance, cultivation, retail operations, logistical support, facility design and construction, and expansion of existing operations. 22

Table of Contents NBC oversees our wholesale equipment and supply business, operated under the name “GC Supply,” which provides turnkey sourcing and stocking services to cultivation, retail and infused products manufacturing facilities. Our products include building materials, equipment, consumables and compliance packaging. There are generally multiple suppliers for the products we sell; however, there are a limited number of manufacturers of certain high-tech cultivation equipment. NBC also provides operational support for our internal cultivation. On July 16, 2021, we entered into an Asset Purchase Agreement with this individual to sell substantially all of the assets of NBC for a total of $150,000 and 10% of profits generated by the buyer in the states of Michigan, Mississippi, and Massachusetts for a period of twelve months from the closing. On August 2, 2021, the sale of NBC was completed.

Results of Operations

The following tables set forth, for the periods indicated, statements of operations data. The tables and the discussion below should be read in conjunction with the accompanying condensed consolidated financial statements and the notes thereto in this report.


	Three months ended September 30,						Percent
	2021		2020		Change		Change
Revenues	$	1,665,642	$	820,068	$	845,574	103	%
Costs and expenses		(2,537,670)		(2,185,910)		(351,760)	16	%
Other expense		(414,962)		930,546		(1,345,508)	(145)	%
Net loss from continuing operations before income taxes		(1,286,990)		(435,296)		(851,694)	196	%
Loss from discontinued operations		(40,605)		(70,968)		30,363	(43)	%
Loss from operations before income taxes	$	(1,327,595)	$	(506,264)	$	(821,331)	162	%


		Nine months ended September 30,									Percent
		2021			2020			Change			Change
Revenues	****	$	3,028,055	****	$	1,391,341	****	$	1,636,714	****	118	%
Costs and expenses			(5,653,952)			(6,342,585)			688,633		(11)	%
Other expense			(2,059,885)			840,919			(2,900,804)		(345)	%
Net loss from continuing operations before income taxes			(4,685,782)			(4,110,325)			(575,457)		14	%
Loss from discontinued operations			(377,134)			(310,490)			(66,644)		21	%
Loss from operations before income taxes		$	(5,062,916)		$	(4,420,815)		$	(642,101)		15	%

Revenues

The addition of our Retail segment contributed to the significant increase in revenues for the three and nine months ended September 30, 2021. See Segment discussions below for further details.

Costs and expenses


	Three months ended September 30,						Percent
	2021		2020		Change		Change
Cost of sales	$	1,473,209	$	304,031	$	1,169,178	385	%
Selling, general and administrative		672,981		751,211		(78,230)	(10)	%
Stock-based compensation		131,836		420,992		(289,156)	(69)	%
Professional fees		144,289		662,687		(518,398)	(78)	%
Depreciation and amortization		115,355		46,989		68,366	145	%
	$	2,537,670	$	2,185,910	$	351,760	16	%

Table of Contents


		Nine months ended September 30,									Percent
	****	2021		****	2020		****	Change		****	Change
Cost of sales		$	2,539,840		$	585,274		$	1,954,566		334	%
Selling, general and administrative			1,853,731			2,464,476			(610,745)		(25)	%
Stock-based compensation			194,120			1,427,931			(1,233,811)		(86)	%
Professional fees			760,437			1,768,714			(1,008,277)		(57)	%
Depreciation and amortization			305,824			96,190			209,634		218	%
		$	5,653,952		$	6,342,585		$	(688,633)		(11)	%

Cost of sales increased year over year due to the addition of the Retail Segment in the third quarter. See Segment discussions below for further details.

Selling, general and administrative expense decreased for the three months and nine months ended September 30, 2021 as compared to September 30, 2020 due to a reduction in employees throughout 2021 and a concerted effort by management to reduce expenses.

Professional fees consist primarily of accounting and legal expenses and decreased for the three and nine months ended September 30, 2021 as compared to the three and nine months ended September 30, 2020 due to the hiring of internal counsel to be more cost effective.

Stock-based compensation included the following:


	Three months ended September 30,						Percent
	2021		2020		Change		Change
Employee awards	$	131,836	$	420,992	$	(289,156)	(69)	%
	$	131,836	$	420,992	$	(289,156)	(69)	%


	Nine months ended September 30,						Percent
	2021		2020		Change		Change
Employee awards	$	194,120	$	1,354,328	$	(1,160,208)	(86)	%
Consulting awards		—		73,603		(73,603)	(100)	%
	$	194,120	$	1,427,931	$	(1,233,811)	(86)	%

Employee awards are issued under our 2020 Omnibus Incentive Plan, which was approved by shareholders on November 23, 2020 and our 2014 Equity Incentive Plan, which was approved by shareholders on June 26, 2015. Expense varies primarily due to the number of stock options granted and the share price on the date of grant. The decrease in expense for the three and nine months ended September 30, 2021 as compared to September 30, 2020 is due to the decrease in the number of options we grant on a quarterly basis and an increase in forfeitures in 2021 due to the departure of our Chief Executive Officer in May 2021, the departure of our Chief Financial Officer in September 2021 and a reduction in workforce in 2020 and 2021.

Other Expense


	Three months ended September 30,						Percent
	2021		2020		Change		Change
Amortization of debt discount and equity issuance costs	$	216,516	$	61,002	$	155,514	255	%
Interest expense		150,503		84,716		65,787	78	%
Loss on extinguishment of debt		233,374		—		233,374	100	%
(Gain) loss on derivative liability		(52,452)		(1,076,264)		1,023,812	(95)	%
Gain on sale of assets		(132,979)		—		(132,979)	(100)	%
	$	414,962	$	(930,546)	$	1,345,508	(145)	%

Table of Contents


	Nine months ended September 30,						Percent
	2021		2020		Change		Change
Amortization of debt discount	$	470,306	$	199,839	$	270,467	135	%
Interest expense		444,186		359,436		84,750	24	%
Loss on extinguishment of debt		233,374		1,186,336		(952,962)	(80)	%
Loss (gain) on derivative liability		1,043,531		(2,447,343)		3,490,874	(143)	%
Other expense (income), net		(131,512)		(139,187)		7,675	(6)	%
	$	2,059,885	$	(840,919)	$	2,900,804	(345)	%

Amortization of debt discount increased during the three and nine months ended September 30, 2021 as compared to September 30, 2020 due to the senior convertible promissory notes with warrants (“10% Notes”) issued in December 2020, February 2021 and April 2021. Interest expense increased during the three and nine months ended September 30, 2021 as compared to September 30, 2020 due to the addition of the 10% Notes with an interest rate of 10%. The gain on warrant derivative liability reflects the change in the fair value of the 2019 Warrants. The loss on extinguishment of debt for the three and nine months ended September 30, 2021 was due to the modification of warrants that occurred on the 15% Warrants during the third quarter. The loss on extinguishment of debt during 2020 is due to the conversion and extension of the SBI debt, and the exchange of the 12% Notes into the 15% Notes that occurred during the first quarter of 2020. See Note 7 of the accompanying unaudited condensed consolidated financial statements for further information. The other expense (income) in 2020 relates to the gain on the sale of the building we recognized as a result of the sale of our corporate office building in March 2020.

Retail


		Three months ended September 30,									Percent	****
	****	2021		****	2020		****	Change		****	Change	****
Revenues		$	855,841		$	—		$	855,841		100	%
Costs and expenses			(891,126)			—			(891,126)		100	%
		$	(35,285)		$	—		$	(35,285)		100	%


	Nine months ended September 30,						Percent
	2021		2020		Change		Change
Revenues	$	855,841	$	—	$	855,841	100	%
Costs and expenses		(891,126)		—		(891,126)	100	%
Segment operating income	$	(35,285)	$	—	$	(35,285)	100	%

With the addition of the TREES Englewood dispensary on September 2, 2021, we have established our retail footprint in the Colorado market and have become a vertically integrated company. The Retail Segment will provide consistent positive cash flows which will significantly contribute to our working capital position. The negative margin reported in the third quarter is primarily due to the inventory being marked to fair market value as of the acquisition date, September 2^nd^, 2021. The company expects this inventory to mostly turn over before year end and start recognizing a positive margin in the 4^th^ quarter of 2021.

Cultivation


		Three months ended September 30,									Percent	****
	****	2021		****	2020		****	Change		****	Change	****
Revenues		$	835,719		$	798,352		$	37,367		5	%
Costs and expenses			(865,490)			(609,381)			(256,109)		42	%
		$	(29,771)		$	188,971		$	(218,742)		(116)	%


		Nine months ended September 30,									Percent	****
	****	2021		****	2020		****	Change		****	Change	****
Revenues		$	2,183,660		$	1,307,527		$	876,133		67	%
Costs and expenses			(2,340,913)			(1,025,507)			(1,315,406)		128	%
		$	(157,253)		$	282,020		$	(439,273)		(156)	%

Table of Contents The increase in revenues for the three and nine months ended September 30, 2021 over prior year is due to selling premium blunts that command a higher price than traditional wholesale cannabis. The decrease in gross margin is due to lower yields caused by several environmental factors.

Liquidity

Sources of liquidity

Our sources of liquidity include cash generated from operations, the cash exercise of common stock options and warrants, debt, and the issuance of common stock or other equity-based instruments. We anticipate our significant uses of resources will include funding operations and developing infrastructure.

In September 2021, we received $1,180,000 in cash in a private placement with certain accredited investors pursuant to the Series A Convertible Preferred Stock to be used for the acquisition of dispensaries and for operating capital. (See Note 10 of the accompanying unaudited condensed consolidated financial statements).

In April 2021, we received $2,300,000 in cash in a private placement with certain accredited investors pursuant to the 10% Notes to be used for the acquisition of dispensaries (See Note 13 of the accompanying unaudited condensed consolidated financial statements).

In February 2021, we received $1,660,000 in cash in a private placement with certain accredited investors pursuant to the 10% Notes.

Sources and uses of cash

We had cash of $2,459,453 and $750,218 as of September 30, 2021 and December 31, 2020, respectively. Our cash flows from operating, investing and financing activities were as follows:


	Nine months ended September 30,
	2021		2020
Net cash used in operating activities	$	(2,489,130)	$	(4,384,372)
Net cash provided by investing activities	$	(936,719)	$	1,264,790
Net cash provided by financing activities	$	5,134,634	$	3,615,000

Net cash used in operating activities decreased in 2021 due to the acquisition of SevenFive Farm and TREES Englewood which provides positive operating cash flows and adjustments relating to non-cash activities.

Net cash provided by investing activities for the nine months ended September 30, 2021 decreased from September 30, 2020 due to the sale of the building in the first quarter of 2020. Net cash used in investing activities for the nine months ended September 30, 2021 consisted of purchase of, Trees Colorado, LLC and the purchase of property and equipment for SevenFive Farms, offset by the sale of our investment during the first quarter and repayment of our notes receivable in the second quarter.

Net cash provided by financing activities for the nine months ended September 30, 2021 related to the payment on notes payable of $200,000, proceeds from notes payable of $3,960,000, proceeds of the preferred stock offering of $1,180,000 and proceeds from the exercise of stock options of $194,634.

Capital Resources

We had no material commitments for capital expenditures as of September 30, 2021. Part of our growth strategy, however, is to acquire operating businesses. We expect to fund such activity through cash on hand, the issuance of debt, common stock, warrants for our common stock or a combination thereof. 26

Table of Contents Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP financial measure. We define Adjusted EBITDA as net income (loss) attributable to common stockholders calculated in accordance with GAAP, adjusted for the impact of stock-based compensation expense, acquisition or disposal-related transaction costs , non-recurring professional fees in relation to litigation and other non-recurring expenses, depreciation and amortization, amortization of debt discounts and equity issuance costs, loss on extinguishment of debt, interest expense, income taxes and certain other non-cash items. Below we have provided a reconciliation of Adjusted EBITDA per share to the most directly comparable GAAP measure, which is net income (loss) per share.

We believe that the disclosure of Adjusted EBITDA provides investors with a better comparison of our period-to-period operating results. We exclude the effects of certain items when we evaluate key measures of our performance internally and in assessing the impact of known trends and uncertainties on our business. We also believe that excluding the effects of these items provides a more comparable view of the underlying dynamics of our operations. We believe such information provides additional meaningful methods of evaluating certain aspects of our operating performance from period to period on a basis that may not be otherwise apparent on a GAAP basis. This supplemental financial information should be considered in addition to, not in lieu of, our condensed consolidated financial statements.

The following table reconciles Adjusted EBITDA to the most directly comparable GAAP measure, which is net loss.


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Loss from operations before income taxes	$	(1,327,595)	$	(506,264)	$	(5,062,916)	$	(4,420,815)
Adjustment for loss from discontinued operations		40,605		70,968		377,134		310,490
Net loss from continuing operations before income taxes		(1,286,990)		(435,296)		(4,685,782)		(4,110,325)
Adjustments:
Stock-based compensation		131,836		420,992		194,120		1,427,931
Depreciation and amortization		115,355		46,989		305,824		96,190
Amortization of debt discount and equity issuance costs		216,516		61,002		470,306		199,839
Loss on extinguishment of debt		233,374		—		233,374		1,186,336
Interest expense		150,503		84,716		444,186		359,436
Gain on sale of assets		(132,979)		—		(131,512)		(139,187)
(Gain) loss on derivative liability		(52,452)		(1,076,264)		1,043,531		(2,447,343)
Transaction costs		35,360		183,793		98,243		318,681
Total adjustments		697,513		(278,772)		2,658,072		1,001,883
Adjusted EBITDA	$	(589,477)	$	(714,068)	$	(2,027,710)	$	(3,108,442)

Off-balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

Critical Accounting Policies

Our unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, and Note 1 to the Unaudited Condensed Consolidated Financial Statements in this Form 10-Q. 27

Table of Contents ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial and Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of management, including our Principal Executive Officer and Principal Financial and Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2021, the end of the period covered by this report. Based on that evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2021.

Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by the Board, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

●	Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
●	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures of are being made only in accordance with authorizations of our management and directors; and
---	---
●	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.
---	---

Because of inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Assessment of Internal Control over Financial Reporting

Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control - Integrated Framework (2013). Based on management’s assessment, management concluded that its internal control over financial reporting was effective as of September 30, 2021, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. 28

Table of Contents Changes in Internal Control over Financial Reporting

None.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In July 2021, the Company was served with a Complaint in the District Court, County of Denver, Colorado, by plaintiff 2353 SB, LLC (“Plaintiff”). Plaintiff and the Company entered into a lease for the premises at 2353 South Broadway, Denver, CO with a term of three (3) years to commence on November 1, 2020. Monthly lease payments were to be $12,866.66. In 2020, the Company made initial payments (first month’s rent and security deposit) of $39,633.32; but subsequently did not take possession of the premises and has made no further payments in respect thereof, as a direct result of the COVID-19 pandemic. The lease contains a ‘force majeure’ clause which includes a provision that neither party is liable for failure to perform its obligations under the lease which have become practicably impossible because of circumstances beyond the reasonable control of the applicable party, including ‘pandemics or outbreak of communicable disease.’

ITEM 1A. RISK FACTORS

As of the date of this report, there have been no material changes to the Risk Factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On September 10, 2021 we issued 1,180 Series A Convertible Preferred Stock to accredited investors. The Series A Convertible Preferred Stock had an issue price of $1,000 per share (previously disclosed on Form 8-K).

On September 10, 2021 we issued warrants to purchase 354,000 shares of our common stock, together with our Series A Convertible Preferred Stock, to accredited investors. The warrants have an exercise price of $1.05 per share and a life of 5 years (previously disclosed on Form 8-K).

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

Table of Contents ITEM 6. EXHIBITS

Exhibits	****
10.1	Offer Letter date September 5, 2021 between the Company and Jessica Bast (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on September 10, 2021)
10.2	Employment agreement dated September 9, 2021 between the Company and Timothy Brown (incorporated by reference to Exhibit 10.2 to our Form 8-K filed on September 10, 2021)
10.3	Certificate of Designations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 4.1 to our Form 8-K filed on September 14, 2021)
10.4	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on September 14, 2021)
10.5	Form of Warrant (incorporated by reference to Exhibit 10.2 to our Form 8-K filed on September 14, 2021)
10.6	Form of ‘A’ Warrant Amendment Agreement (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on September 21, 2021)
10.7	Form of ‘B’ Warrant Amendment Agreement (incorporated by reference to Exhibit 10.2 to our Form 8-K filed on September 21, 2021)
10.8	Amendment to Employment Agreement date October 1, 2021 between the Company and John Barker Dalton (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on October 4, 2021)
10.9	Audited financial statements of TDM, LLC as of and for the years ended December 31, 2020 and 2019 (incorporated by reference to Exhibit 99.1 to our Form 8-K/A filed on October 19, 2021)
31.1	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Table of Contents SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GENERAL CANNABIS CORP
Date: November 12, 2021		/s/ Adam Hershey
		Adam Hershey, Interim Chief Executive Officer
		Principal Executive Officer

		/s/ Jessica Bast
		Jessica Bast, Chief Financial Officer
		Principal Financial and Accounting Officer

Exhibit 31.1

CERTIFICATIONS

Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002

(Subsections (A) And (B) Of Section 1350, Chapter 63 of Title 18, United States Code)

I, Adam Hershey, certify that:

I have reviewed this quarterly report on Form 10-Q of General Cannabis Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant's internal control over financial reporting.


November 12, 2021		/s/ Adam Hershey
		Adam Hershey, Interim Chief Executive Officer,
		Principal Executive Officer

Exhibit 31.2

CERTIFICATIONS

Pursuant To Section 906 of the Sarbanes-Oxley Act Of 2002

(Subsections (A) And (B) Of Section 1350, Chapter 63 of Title 18, United States Code)

I, Jessica Bast, certify that:

I have reviewed this quarterly report on Form 10-Q of General Cannabis Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant's internal control over financial reporting.


November 12, 2021		/s/ Jessica Bast
		Jessica Bast, Chief Financial Officer, Principal Financial
		and Accounting Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of General Cannabis Corporation (the "Company") on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission (the "Report"), Adam Hershey, the Company’s Principal Executive, and Jessica Bast, the Company’s Principal Financial and Accounting Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.


November 12, 2021		/s/ Adam Hershey
		Adam Hershey, Interim Chief Executive Officer,
		Principal Executive Officer


November 12, 2021		/s/ Jessica Bast
		Jessica Bast, Chief Financial Officer,
		Principal Financial and Accounting Officer